Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado, USA.
Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
J Med Virol. 2024 Mar;96(3):e29541. doi: 10.1002/jmv.29541.
Effective therapies for reducing post-acute sequelae of COVID-19 (PASC) symptoms are lacking. Evaluate the association between monoclonal antibody (mAb) treatment or COVID-19 vaccination with symptom recovery in COVID-19 participants. The longitudinal survey-based cohort study was conducted from April 2021 to January 2022 across a multihospital Colorado health system. Adults ≥18 years with a positive SARS-CoV-2 test were included. Primary exposures were mAb treatment and COVID-19 vaccination. The primary outcome was time to symptom resolution after SARS-CoV-2 positive test date. The secondary outcome was hospitalization within 28 days of a positive SARS-CoV-2 test. Analysis included 1612 participants, 539 mAb treated, and 486 with ≥2 vaccinations. Time to symptom resolution was similar between mAb treated versus untreated patients (adjusted hazard ratio (aHR): 0.90, 95% CI: 0.77-1.04). Time to symptom resolution was shorter for patients who received ≥2 vaccinations compared to those unvaccinated (aHR: 1.56, 95% CI: 1.31-1.88). 28-day hospitalization risk was lower for patients receiving mAb therapy (adjusted odds ratio [aOR]: 0.31, 95% CI: 0.19-0.50) and ≥2 vaccinations (aOR: 0.33, 95% CI: 0.20-0.55), compared with untreated or unvaccinated status. Analysis included 1612 participants, 539 mAb treated, and 486 with ≥2 vaccinations. Time to symptom resolution was similar between mAb treated versus untreated patients (adjusted hazard ratio (aHR): 0.90, 95% CI: 0.77-1.04). Time to symptom resolution was shorter for patients who received ≥2 vaccinations compared to those unvaccinated (aHR: 1.56, 95% CI: 1.31-1.88). 28-day hospitalization risk was lower for patients receiving mAb therapy (adjusted odds ratio [aOR]: 0.31, 95% CI: 0.19-0.50) and ≥2 vaccinations (aOR: 0.33, 95% CI: 0.20-0.55), compared with untreated or unvaccinated status. COVID-19 vaccination, but not mAb therapy, was associated with a shorter time to symptom resolution. Both were associated with lower 28-day hospitalization.
针对 COVID-19（PASC）症状的有效治疗方法仍然缺乏。评估单克隆抗体（mAb）治疗或 COVID-19 疫苗接种与 COVID-19 参与者症状恢复之间的关联。这项基于纵向调查的队列研究于 2021 年 4 月至 2022 年 1 月在科罗拉多州的一个多医院医疗系统中进行。纳入了年龄≥18 岁、SARS-CoV-2 检测呈阳性的成年人。主要暴露因素是 mAb 治疗和 COVID-19 疫苗接种。主要结局是 SARS-CoV-2 阳性检测日期后症状缓解的时间。次要结局是 SARS-CoV-2 阳性检测后 28 天内住院。分析纳入了 1612 名参与者，其中 539 名接受 mAb 治疗，486 名接受≥2 剂疫苗接种。与未接受治疗的患者相比，接受 mAb 治疗的患者症状缓解时间相似（校正后的危险比[aHR]：0.90，95%CI：0.77-1.04）。与未接种疫苗的患者相比，接受≥2 剂疫苗接种的患者症状缓解时间更短（aHR：1.56，95%CI：1.31-1.88）。与未接受治疗或未接种疫苗的患者相比，接受 mAb 治疗（校正后的优势比[aOR]：0.31，95%CI：0.19-0.50）和接受≥2 剂疫苗接种（aOR：0.33，95%CI：0.20-0.55）的患者 28 天住院风险较低。
